logo
Plus   Neg
Share
Email
Comment

Givaudan 9-month Sales Rise, Backs Mid-term View - Update

Givaudan AG (GVDBF.PK), a Swiss manufacturer of fragrance and flavor products, Thursday reported growth in sales for the first nine months of the year, with increases in both divisions. The company backed its mid-term growth target.

Sales rose 2.7 percent to 3.318 billion Swiss francs ($3.64 billion) from 3.231 billion francs in the same period last year. The increase was 5 percent on a like-for-like basis.

Fragrance Division sales advanced 3 percent to 1.579 billion francs and improved 4.5 percent on a like-for-like basis.

Within the business, sales of compounds increased 3.7 percent. On a like-for-like basis, Fine Fragrance sales improved, driven by growth in both mature and developing markets as new business more than compensated for erosion.

The Consumer Products business grew 6.2 percent on a like-for-like basis against double-digit comparables last year.

Sales of Fragrance Ingredients declined 2.6 percent on a like-for-like basis, as good performance of speciality sales in the third quarter could not make up for the continued price pressure in the commodities sales segment.

Flavour Division sales rose 2.4 percent to 1.739 billion francs and like-for-like sales growth was 5.4 percent, driven by increases in the developing markets, particularly in Asia Pacific markets that saw solid new wins and growth of existing business.

Sales in the July to September period fell to 1.093 billion francs from 1.105 billion francs with a 1.3 percent drop in the Fragrance Division and a 0.9 percent decline in the Flavour Division.

Volume growth in all markets in the third quarter was consistent with those in the first six months of the year and pricing effects were negligible.

Mid-term, the overall objective of the company is still to grow organically between 4.5 and 5.5 percent per annum, assuming a market growth of 2-3 percent.

Givaudan continues to expect to outgrow the underlying market and continue to achieve its industry-leading EBITDA margin while improving its annual free cash flow to between 14 and 16 percent of sales by 2015.

The company also confirmed its intention to return above 60 percent of the company's free cash flow to shareholders while maintaining a medium term leverage ratio target below 25 percent.

The stock rose 1.1 percent in Zurich on Wednesday to close at 1,244 francs.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Amid a government shutdown, the Senate voted Monday to move forward on a short-term spending bill to re-open the government. The Senate voted 81 to 18 in favor of limiting debate on the bill, which would fund the government through February 8th. Opera, a web browser for Windows, macOS, and Linux operating systems, has added cryptocurrency mining protection to its mobile browsers. It is part of the browser's ad blocker function. In its desktop-based versions, Opera had introduced cryptocurrency miner protection in early January. French drug giant Sanofi SA Monday announced an agreement to buy US-based hemophilia drugmaker Bioverativ Inc. (BIVV) for around $11.6 billion. The deal expands Sanofi's presence in specialty care and strengthens leadership in rare diseases. Sanofi shares were losing around 4 percent in the early morning trading in Paris.
comments powered by Disqus
Follow RTT